Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)

Trial Profile

Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Olmesartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms SUPPORT
  • Most Recent Events

    • 15 Nov 2017 Results (n=554) presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 10 Jun 2017 Biomarkers information updated
    • 15 Sep 2016 Results (n=1138) of a subanlysis of SUPPORT trial assessing the influence of Left Ventricular Ejection Fraction on the effects of olmesartan in heart failure, published in the Circulation Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top